Premium
Fe(III)‐Shikonin Supramolecular Nanomedicine for Combined Therapy of Tumor via Ferroptosis and Necroptosis (Adv. Healthcare Mater. 2/2022)
Author(s) -
Feng Wenjie,
Shi Wanrui,
Liu Shuwei,
Liu Huiwen,
Liu Yi,
Ge Pengfei,
Zhang Hao
Publication year - 2022
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202270013
Subject(s) - necroptosis , nanomedicine , glutathione , intracellular , programmed cell death , reactive oxygen species , cancer research , chemistry , pharmacology , nanotechnology , materials science , medicine , biochemistry , apoptosis , enzyme , nanoparticle
Enzyme‐Responsive Drug Release In article number 2101926, Yi Liu, Pengfei Ge, Hao Zhang, and co‐workers construct a Fe(III)‐Shikonin metal‐polyphenol‐coordinated supramolecular nanomedicine for combined therapy of tumors. The as‐prepared nanomedicine will disassemble into Fe 2+ and Shikonin in response to the high concentration of glutathione in tumor cells, followed by the up‐regulation of the intracellular reactive oxygen species level and the depletion of the intracellular glutathione level, resulting in the tumor cell death via ferroptosis and necroptosis.